MacroGenics down on detailed OS data for margetuximab

After getting a bump in May on data released ahead of ASCO, MacroGenics lost $3.13 (17%) to $15.58 on Tuesday following detailed overall survival data from the Phase III SOPHIA trial

Read the full 318 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE